Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 19Myeloid 9Lymphoid 6Thoracic 3Other solid neoplasm 3Tumor-Agnostic 2Plasma cell 2Sarcoma 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

Radiotherapy 221Cyclophosphamide 211Doxorubicin 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 81Irinotecan 79pembrolizumab 75Radiation 70Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Surgical Procedures, Operative 57Peripheral Blood Stem Cell Transplantation 57Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pevonedistat × Sarcoma × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡